Fritzler M J
Faculty of Medicine, University of Calgary, AB Canada.
Lupus. 1994 Dec;3(6):455-9. doi: 10.1177/096120339400300605.
A number of drugs have recently been implicated in a syndrome that resembles systemic lupus erythematosus. One of the difficulties in many of these patients is that the signs, symptoms and serological abnormalities reported in these patients may be a natural consequence of the primary diseases rather than the incriminated drug. A second problem with the studies is a lack of uniform reporting of the techniques used to detect autoantibodies. For example, a patient that has a highly positive ANA with a homogeneous pattern of staining or a positive LE cell test usually has antibodies directed against chromatin components (DNA, histones, high mobility group (HMG) proteins). The discrepancies in clinical criteria and the serological techniques in many of these reports, emphasize the importance of using guidelines for the diagnosis of drug-induced or drug-related lupus. In the future, it appears that the increased use of biological response modifiers such as interferon-alpha and other cytokines may prompt more reports of lupus syndromes associated with their use.
最近,许多药物被认为与一种类似系统性红斑狼疮的综合征有关。这些患者中的许多人面临的一个困难是,这些患者报告的体征、症状和血清学异常可能是原发性疾病的自然结果,而非涉事药物所致。这些研究的第二个问题是缺乏用于检测自身抗体的技术的统一报告。例如,抗核抗体(ANA)高度阳性且染色呈均质型或狼疮细胞试验阳性的患者,通常具有针对染色质成分(DNA、组蛋白、高迁移率族(HMG)蛋白)的抗体。许多此类报告中临床标准和血清学技术的差异,强调了使用药物性或药物相关性狼疮诊断指南的重要性。未来,似乎诸如α干扰素和其他细胞因子等生物反应调节剂使用的增加,可能会促使更多与它们使用相关的狼疮综合征报告出现。